Is Propofol Safe when Administered to Cirrhotic Patients During Sedative Endoscopy?

Overview

Journal Korean J Intern Med

Specialty General Medicine

Date 2014 Feb 28

PMID 24574834

Citations 13

Authors

Sang Jun Suh

Hyung Joon Yim

Eileen L Yoon

Beom Jae Lee

Jong Jin Hyun

Sung Woo Jung

Ja Seol Koo

Ji Hoon Kim

Kyung Jin Kim

Rok Son Choung

Yeon Seok Seo

Jong Eun Yeon

Soon Ho Um

Kwan Soo Byun

Sang Woo Lee

Jai Hyun Choi

Ho Sang Ryu

Affiliations

Soon will be listed here.

Abstract

Background/aims: In patients with liver cirrhosis, drugs acting on the central nervous system can lead to hepatic encephalopathy and the effects may be prolonged. Recently, misuse of propofol has been reported and the associated risk of death have become an issue. Propofol is commonly used during sedative endoscopy; therefore, its safety in high-risk groups must be further investigated. We performed a pilot study of the safety and efficacy of propofol during endoscopy in Korean patients with cirrhosis.

Methods: Upper gastrointestinal endoscopy was performed under sedation with propofol along with careful monitoring in 20 patients with liver cirrhosis and 20 control subjects. The presence or development of hepatic encephalopathy was assessed using the number connection test and neurologic examination.

Results: Neither respiratory depression nor clinically significant hypotension were observed. Immediate postanesthetic recovery at 5 and 10 minutes after the procedure was delayed in the cirrhotic patients compared with the control group; however, at 30 minutes, the postanesthetic recovery was similar in both groups. Baseline psychomotor performance was more impaired in cirrhotic patients, but propofol was not associated with deteriorated psychomotor function even in cirrhotic patients with a minimal hepatic encephalopathy.

Conclusions: Sedation with propofol was well tolerated in cirrhotic patients. No newly developed hepatic encephalopathy was observed.

Citing Articles

Safety, pharmacokinetics and pharmacodynamics of a novel γ-aminobutyric acid (GABA) receptor potentiator, HSK3486, in Chinese patients with hepatic impairment.

Hu Y, Li X, Liu J, Chen H, Zheng W, Zhang H Ann Med. 2022; 54(1):2769-2780.

PMID: 36217101 PMC: 9559057. DOI: 10.1080/07853890.2022.2129433.

Safety, Efficacy and High-Quality Standards of Gastrointestinal Endoscopy Procedures in Personalized Sedoanalgesia Managed by the Gastroenterologist: A Retrospective Study.

Rizzi M, Panzera F, Panzera D, DAscoli B J Pers Med. 2022; 12(7).

PMID: 35887668 PMC: 9318151. DOI: 10.3390/jpm12071171.

Pre-procedural Preparation and Sedation for Gastrointestinal Endoscopy in Patients with Advanced Liver Disease.

Fung B, Leon D, Beck L, Tabibian J Dig Dis Sci. 2021; 67(7):2739-2753.

PMID: 34169430 DOI: 10.1007/s10620-021-07111-1.

Propofol midazolam sedation for elective endoscopy in patients with cirrhosis: A systematic review and meta-analysis of randomized controlled trials.

Guacho J, Hourneaux de Moura D, Ribeiro I, da Ponte Neto A, Singh S, Tucci M World J Gastrointest Endosc. 2020; 12(8):241-255.

PMID: 32879659 PMC: 7443824. DOI: 10.4253/wjge.v12.i8.241.

Propofol alone prevents worsening hepatic encephalopathy rather than midazolam alone or combined sedation after esophagogastroduodenoscopy in compensated or decompensated cirrhotic patients.

Jeong J, Jung K, Seo K, Yun B, Han B, Lee S Eur J Gastroenterol Hepatol. 2020; 32(8):1054-1061.

PMID: 32433420 PMC: 7337114. DOI: 10.1097/MEG.0000000000001755.

References

Bajaj J, Saeian K, Schubert C, Hafeezullah M, Franco J, Varma R . Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology. 2009; 50(4):1175-83. PMC: 2757520. DOI: 10.1002/hep.23128. View

Das A, Dhiman R, Saraswat V, Verma M, Naik S . Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. J Gastroenterol Hepatol. 2001; 16(5):531-5. DOI: 10.1046/j.1440-1746.2001.02487.x. View

Dhiman R, Saraswat V, Verma M, Naik S . Figure connection test: a universal test for assessment of mental state. J Gastroenterol Hepatol. 1995; 10(1):14-23. DOI: 10.1111/j.1440-1746.1995.tb01041.x. View

Haq M, Faisal N, Khalil A, Haqqi S, Shaikh H, Arain N . Midazolam for sedation during diagnostic or therapeutic upper gastrointestinal endoscopy in cirrhotic patients. Eur J Gastroenterol Hepatol. 2012; 24(10):1214-8. DOI: 10.1097/MEG.0b013e328356ae49. View

Servin F, Cockshott I, Farinotti R, Haberer J, Winckler C, Desmonts J . Pharmacokinetics of propofol infusions in patients with cirrhosis. Br J Anaesth. 1990; 65(2):177-83. DOI: 10.1093/bja/65.2.177. View

Li Y, Nie Y, Sha W, Zeng Z, Yang F, Ping L . Prevalence of subclinical hepatic encephalopathy in cirrhotic patients in China. World J Gastroenterol. 2004; 10(16):2397-401. PMC: 4576296. DOI: 10.3748/wjg.v10.i16.2397. View

Kranioti E, Mavroforou A, Mylonakis P, Michalodimitrakis M . Lethal self administration of propofol (Diprivan). A case report and review of the literature. Forensic Sci Int. 2006; 167(1):56-8. DOI: 10.1016/j.forsciint.2005.12.027. View

Aldrete J, Kroulik D . A postanesthetic recovery score. Anesth Analg. 1970; 49(6):924-34. View

Costela J, Jimenez R, Calvo R, Suarez E, Carlos R . Serum protein binding of propofol in patients with renal failure or hepatic cirrhosis. Acta Anaesthesiol Scand. 1996; 40(6):741-5. DOI: 10.1111/j.1399-6576.1996.tb04521.x. View

10.

Kirby R, Colaw J, Douglas M . Death from propofol: accident, suicide, or murder?. Anesth Analg. 2009; 108(4):1182-4. DOI: 10.1213/ane.0b013e318198d45e. View

11.

Jeong S, Lee H, Kim W, Jeong C, Lee S, Yoon M . Increase of paradoxical excitement response during propofol-induced sedation in hazardous and harmful alcohol drinkers. Br J Anaesth. 2011; 107(6):930-3. DOI: 10.1093/bja/aer275. View

12.

Ortiz M, Jacas C, Cordoba J . Minimal hepatic encephalopathy: diagnosis, clinical significance and recommendations. J Hepatol. 2005; 42 Suppl(1):S45-53. DOI: 10.1016/j.jhep.2004.11.028. View

13.

Cheung R, Cooper S, Keeffe E . Endoscopic gastrointestinal manifestations of liver disease. Gastrointest Endosc Clin N Am. 2001; 11(1):15-44. View

14.

Weissenborn K, Ruckert N, Hecker H, Manns M . The number connection tests A and B: interindividual variability and use for the assessment of early hepatic encephalopathy. J Hepatol. 1998; 28(4):646-53. DOI: 10.1016/s0168-8278(98)80289-4. View

15.

McCrea M, Cordoba J, Vessey G, Blei A, Randolph C . Neuropsychological characterization and detection of subclinical hepatic encephalopathy. Arch Neurol. 1996; 53(8):758-63. DOI: 10.1001/archneur.1996.00550080076015. View

16.

Romero-Gomez M, Cordoba J, Jover R, del Olmo J, Ramirez M, Rey R . Value of the critical flicker frequency in patients with minimal hepatic encephalopathy. Hepatology. 2007; 45(4):879-85. DOI: 10.1002/hep.21586. View

17.

Rivera Ramos J, Rodriguez Leal C . Review of the final report of the 1998 Working Party on definition, nomenclature and diagnosis of hepatic encephalopathy. Ann Hepatol. 2012; 10 Suppl 2:S36-9. View

18.

Riphaus A, Gstettenbauer T, Frenz M, Wehrmann T . Quality of psychomotor recovery after propofol sedation for routine endoscopy: a randomized and controlled study. Endoscopy. 2006; 38(7):677-83. DOI: 10.1055/s-2006-925244. View

19.

Romero-Gomez M, Boza F, Garcia-Valdecasas M, Garcia E, Aguilar-Reina J . Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol. 2001; 96(9):2718-23. DOI: 10.1111/j.1572-0241.2001.04130.x. View

20.

Vargo J . Propofol: a gastroenterologist's perspective. Gastrointest Endosc Clin N Am. 2004; 14(2):313-23. DOI: 10.1016/j.giec.2004.01.005. View